Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Bacterial Infection
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Infection Rate
100%
Epstein-Barr Virus Reactivation
100%
Rituximab Therapy
100%
Post-transplant Lymphoproliferative Disorder
66%
Excess Risk
66%
Graft-versus-host Disease (GvHD)
33%
Immune Reconstitution
33%
Rituximab
33%
B Cells
33%
Immune Deficiency
33%
β-cell Dysfunction
33%
Infection-related Mortality
33%
Reconstitution
33%
Viral Infection
33%
Epstein-Barr Virus Infections
33%
Fungal Infection
33%
Non-relapse Mortality
33%
Epstein-Barr Virus
33%
High Mortality
33%
Cumulative Incidence
33%
Donor Type
33%
Should Be Given
33%
Decreased Risk
33%
Source Type
33%
Stem Cell Source
33%
Late Infection
33%
Stem Cell Donor
33%
Immunoglobulin Replacement
33%
Anti-thymoglobulin
33%
Medicine and Dentistry
Rituximab
100%
Epstein Barr Virus
100%
Infection Rate
100%
Bacterial Infection
100%
Allogeneic Hematopoietic Stem Cell Transplantation
100%
Virus Reactivation
100%
B Cell
66%
Lymphoproliferative Disease
66%
Immune Reconstitution
33%
Infection
33%
Immunoglobulin
33%
Virus Infection
33%
Mycosis
33%
Acute Graft Versus Host Disease
33%
Stem Cell
33%
Epstein-Barr Virus Infection
33%
Cumulative Incidence
33%
Immune Deficiency
33%
Immunology and Microbiology
Rituximab
100%
Allogeneic Hematopoietic Stem Cell Transplantation
100%
Infection Rate
100%
Virus Reactivation
100%
Epstein Barr Virus
100%
Infection
100%
Immunodeficiency
25%
B Cell
25%
Viral Disease
25%
Intravenous Immunoglobulin
25%
Immune Reconstitution
25%
Stem Cell
25%
Acute Graft Versus Host Disease
25%
B-Cell Deficiency
25%